Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get Started
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Bevacizumab (Intravenous Route)
Drug Information provided by: MicromedexUS Brand Names
|
Description
Bevacizumab is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called non-squamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma.
Bevacizumab is a substance that helps the body fight cancer. It prevents the growth of certain types of blood vessels to cancer cells. This helps to decrease the growth of cancer cells by starving the cells of nutrients that are needed to grow.
Bevacizumab is also used in combination with paclitaxel (Taxol®) to treat a certain type of breast cancer called metastatic HER2-negative breast cancer. This medicine should not be used to treat breast cancer that is worse after receiving other cancer medicines, such as doxorubicin (Adriamycin®, Rubex®) or docetaxel (Taxotere®).
Bevacizumab is to be administered only by or under the immediate supervision of your doctor.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, bevacizumab is used in certain patients with the following medical conditions:
- Glioblastoma multiforme, recurrent, following prior treatment with temozolomide (used for a certain type of brain cancer that is getting worse or not responding to treatment).
- Metastatic colorectal cancer, first-line therapy, in combination with capecitabine and oxaliplatin (used together with other medicines for cancer of the colon or rectum that has spread to other areas of the body).
- Metastatic renal cell carcinoma, first-line treatment, in combination with interferon alfa-2a (used together with other medicines for cancer of the kidney that has spread to other areas of the body).
This product is available in the following dosage forms:
- Solution
